Q-omics provides the consensus-scored TENM2 profile across patient tissues and cancer cell-line models. TENM2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TENM2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, TENM2 RNA expression shows 16,431 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where TENM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TENM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TENM2 survival associations across molecular data types. TENM2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TENM2 RNA expression–survival associations across cancer types. High TENM2 expression shows unfavorable associations in MESO, SKCM, HNSC, BLCA, LUAD and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TENM2 RNA expression.
This table summarizes TENM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TENM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TENM2 shows lower tumor expression in KIRP, THCA, KIRC and BRCA and higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher TENM2 RNA expression in tumor versus normal tissue (log2 FC = +3.543, t-test p < 0.001).
This table shows molecular features associated with TENM2 in patient tissues and cancer cell lines. In patient samples, TENM2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TENM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
